Supraventricular tachycardia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 9,385 adverse event reports that record the MedDRA preferred term Supraventricular tachycardia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 458 reports in the 12 months to June 2026 and 451 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,030 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 458 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 25.9% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 115 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Supraventricular tachycardia name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetylsalicylic Acid		34
Adempas	Soluble guanylate cyclase stimulator	25
Adenosine	Adenosine receptor agonist	47
Albuterol	beta2-Adrenergic agonist	55
Alendronate sodium	Bisphosphonate	42
Ambrisentan	Endothelin receptor antagonist	46
Amiodarone		69
Amlodipine	Calcium channel blocker	63
Aripiprazole	Atypical antipsychotic	33
Aspirin	Nonsteroidal anti-inflammatory drug	56
Atezolizumab	Programmed death Receptor-1 blocking antibody	28
Atorvastatin		26
Avandamet		35
Avandia		217
Avastin	Vascular endothelial growth factor inhibitor	42
Avonex	Interferon beta	38
Bevacizumab	Vascular endothelial growth factor inhibitor	72
Bisoprolol	beta-Adrenergic blocker	56
Bisoprolol fumarate	beta-Adrenergic blocker	25
Bupropion	Aminoketone	30
Carboplatin	Platinum-based drug	145
Carvedilol	alpha-Adrenergic blocker	60
Cisplatin	Platinum-based drug	88
Clarithromycin	Macrolide antimicrobial	39
Clopidogrel	P2Y12 platelet inhibitor	47
Clozapine	Atypical antipsychotic	27
Cyclophosphamide	Alkylating drug	103
Cytarabine	Nucleoside metabolic inhibitor	51
Darvon		26
Dexamethasone	Corticosteroid	117
Diazepam	Benzodiazepine	35
Digoxin	Cardiac glycoside	173
Docetaxel	Microtubule inhibitor	39
Doxorubicin	Anthracycline topoisomerase inhibitor	35
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	36
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	29
Enbrel	Tumor necrosis factor blocker	55
Entresto	Angiotensin 2 receptor blocker	48
Epinephrine	Catecholamine	45
Etoposide	Topoisomerase inhibitor	69
Fentanyl	Opioid agonist	32
Flecainide		48
Fluorouracil	Nucleoside metabolic inhibitor	91
Fluoxetine	Serotonin reuptake inhibitor	25
Fluticasone Propionate Salmeterol Xinafoate		28
Fosamax	Bisphosphonate	101
Furosemide	Loop diuretic	49
Gabapentin	Anti-epileptic agent	34
Gilenya	Sphingosine 1-phosphate receptor modulator	35
Humira		193
Hydrochlorothiazide	Thiazide diuretic	65
Ibrutinib (form s4)	Kinase inhibitor	32
Ibuprofen	Nonsteroidal anti-inflammatory drug	29
Imbruvica	Kinase inhibitor	69
Infliximab	Tumor necrosis factor blocker	34
Levetiracetam		34
Levothyroxine		28
Linagliptin	Dipeptidyl peptidase 4 inhibitor	30
Lisinopril	Angiotensin converting enzyme inhibitor	33
Metformin	Biguanide	64
Methotrexate	Folate analog metabolic inhibitor	89
Methylprednisolone	Corticosteroid	39
Metoprolol	beta-Adrenergic blocker	78
Midazolam	Benzodiazepine	27
Mirtazapine		41
Mounjaro	GLP-1 receptor agonist	27
Mycophenolate mofetil	Antimetabolite immunosuppressant	42
Nivolumab	Programmed death Receptor-1 blocking antibody	52
Nuvaring	Estrogen	32
Omeprazole	Proton pump inhibitor	43
Ondansetron	Serotonin-3 receptor antagonist	41
Opsumit	Endothelin receptor antagonist	61
Oxaliplatin	Platinum-based drug	67
Paclitaxel	Microtubule inhibitor	81
Pantoprazole	Proton pump inhibitor	56
Paxil	Serotonin reuptake inhibitor	70
Pembrolizumab	Programmed death Receptor-1 blocking antibody	27
Prednisolone	Corticosteroid	27
Prednisone	Corticosteroid	101
Propofol	General anesthetic	60
Propranolol	beta-Adrenergic blocker	41
Quetiapine	Atypical antipsychotic	48
Ramipril	Angiotensin converting enzyme inhibitor	41
Remicade	Tumor necrosis factor blocker	62
Remodulin	Prostacycline vasodilator	72
Revlimid	Thalidomide analog	86
Ribavirin	Nucleoside analog antiviral	30
Risperidone	Atypical antipsychotic	52
Rituximab	CD20-directed cytolytic antibody	89
Rosuvastatin	HMG-CoA reductase inhibitor	32
Seroquel	Atypical antipsychotic	30
Sertraline	Serotonin reuptake inhibitor	30
Simvastatin	HMG-CoA reductase inhibitor	50
Sotalol	Antiarrhythmic	31
Symbicort	Corticosteroid	30
Tacrolimus	Calcineurin inhibitor immunosuppressant	50
Taxol		29
Tecfidera		33
Telmisartan	Angiotensin 2 receptor blocker	32
Theophylline	Methylxanthine	28
Tiotropium bromide	Anticholinergic	39
Tracleer	Endothelin receptor antagonist	59
Tramadol		27
Trastuzumab	HER2/neu receptor antagonist	43
Trimetazidine		27
Tysabri	Integrin receptor antagonist	35
Uptravi	Prostacyclin receptor agonist	35
Velcade	Proteasome inhibitor	47
Veletri	Prostacycline vasodilator	33
Venetoclax	BCL-2 inhibitor	37
Verapamil		52
Vincristine		37
Vioxx		118
Xyrem	Central nervous system depressant	64
Yasmin		25

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 51 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Supraventricular tachycardia name, in order of name
Class	Reports with this term
Alkylating drug	128
alpha-Adrenergic blocker	80
Aminoketone	57
Angiotensin 2 receptor blocker	136
Angiotensin converting enzyme inhibitor	88
Anthracycline topoisomerase inhibitor	78
Anti-epileptic agent	107
Antiarrhythmic	81
Anticholinergic	67
Antimetabolite immunosuppressant	57
Atypical antipsychotic	292
Benzodiazepine	117
beta-Adrenergic blocker	283
beta2-Adrenergic agonist	83
Biguanide	70
Bisphosphonate	163
Calcineurin inhibitor immunosuppressant	77
Calcium channel blocker	74
Cardiac glycoside	173
Catecholamine	59
CD20-directed cytolytic antibody	139
Central nervous system depressant	74
Corticosteroid	362
Endothelin receptor antagonist	211
Folate analog metabolic inhibitor	115
General anesthetic	88
GLP-1 receptor agonist	108
HER2/neu receptor antagonist	72
HMG-CoA reductase inhibitor	100
Integrin receptor antagonist	61
Interferon beta	61
Kinase inhibitor	299
Loop diuretic	60
Macrolide antimicrobial	59
Microtubule inhibitor	142
Nonsteroidal anti-inflammatory drug	126
Nucleoside metabolic inhibitor	250
Opioid agonist	102
P2Y12 platelet inhibitor	75
Platinum-based drug	300
Programmed death Receptor-1 blocking antibody	137
Prostacycline vasodilator	150
Proteasome inhibitor	100
Proton pump inhibitor	172
Serotonin and norepinephrine reuptake inhibitor	78
Serotonin reuptake inhibitor	235
Thalidomide analog	123
Thiazide diuretic	65
Topoisomerase inhibitor	73
Tumor necrosis factor blocker	201
Vascular endothelial growth factor inhibitor	116

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Supraventricular tachycardia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Supraventricular tachycardia
Age	Reports	Share
Under 2	199	2.1%
2 to 11	167	1.8%
12 to 17	143	1.5%
18 to 44	1,339	14.3%
45 to 64	2,427	25.9%
65 to 74	1,460	15.6%
75 and over	898	9.6%
Age not given	2,752	29.3%

Sex of the patient in the reports that record Supraventricular tachycardia
Sex	Reports	Share
Female	5,003	53.3%
Male	3,526	37.6%
Unknown or not given	856	9.1%

Age and sex are as the report gives them. 53.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Supraventricular tachycardia: adverse event reports that record this term. https://reportedreactions.com/reaction/supraventricular-tachycardia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Supraventricular tachycardia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page